TRANSGENE (EPA:TNG) | Finanzwire

Basculer en Français

9562	Companies
188958	Keywords
120655	Articles
100824	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 11/25/2025 at 19:15, 26 days 14 hours ago

Transgene launches a fundraising campaign for approximately 105 million euros
Transgene launches a fundraising of approximately 105 million euros through new share issuance to investors. Funding to advance myvac program for personalized cancer vaccines and ensure financial stability until early 2028

Fundraising Financial Stability Cancer Vaccines Transgene Myvac Program
BRIEF

published on 11/06/2025 at 08:35, 1 month 16 days ago

Transgene to Present VacDesignR® Tool at ESMO AI 2025

Transgene VacDesignR® INTV ESMO AI 2025 HPV-negative Cancer
PRESS RELEASE

published on 11/06/2025 at 08:30, 1 month 16 days ago

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Transgene to present VacDesignR® tool at ESMO-AI 2025 for optimized cancer vaccine design. Tool enhances virus efficiency and yield for individualized therapies

Cancer Vaccines Computational Tool Transgene VacDesignR ESMO-AI 2025
BRIEF

published on 11/04/2025 at 17:55, 1 month 17 days ago

Transgene presents its progress and financial situation as of Q3 2025

Funding Immunotherapy Transgene TG4050 SITC 2025
PRESS RELEASE

published on 11/04/2025 at 17:50, 1 month 17 days ago

Transgene Provides Business and Financial Update for Q3 2025
Transgene provides business and financial update for Q3 2025, including immunogenicity data of INTV TG4050 in Phase I study on HNSCC. Company focuses on cancer immunotherapies

Financial Update Transgene INTV TG4050 Cancer Immunotherapies HNSCC
BRIEF

published on 10/20/2025 at 08:35, 2 months 2 days ago

Transgene and BioInvent's BT-001 Shows Promising Antitumor Activity

Cancer Immunotherapy Transgene Oncolytic Virus BT-001 Antitumoral Activity
PRESS RELEASE

published on 10/20/2025 at 08:30, 2 months 2 days ago

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
Transgene and BioInvent's BT-001 oncolytic virus in combination with pembrolizumab shows positive antitumoral activity in refractory tumors. Exciting clinical data presented at ESMO 2025

Transgene Oncolytic Virus BioInvent BT-001 Pembrolizumab
BRIEF

published on 06/13/2025 at 08:35, 6 months 9 days ago

Transgene Engages with Key Biotech Industry Platforms

Cancer Treatment Clinical Data Immunotherapy Transgene Biotech Meetings
PRESS RELEASE

published on 06/13/2025 at 08:30, 6 months 9 days ago

Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Transgene to participate in upcoming meetings with biotech industry leaders to discuss positive clinical data on neoantigen cancer vaccine TG4050 and present innovative immunotherapies. Learn more at www.transgene.com

Biotech Industry Clinical Data Transgene Immunothérapies Neoantigen Cancer Vaccine
BRIEF

published on 06/01/2025 at 19:20, 6 months 20 days ago

Transgene and NEC: Promising progress with the TG4050 vaccine

Immunotherapy Transgene Therapeutic Vaccine Clinical Phase Neoantigens

Accesswire

Published on 12/22/2025 at 08:05, 2 hours ago

Tocvan Begins Trenching Material for the Pilot Mine and Pushes Ahead With Infrastructure Development
Published on 12/20/2025 at 00:30, 2 days 9 hours ago

Alphinat Announces a Profit of $120,155 for Fiscal Year Ended August 31, 2025
Published on 12/19/2025 at 22:00, 2 days 12 hours ago

GMV Minerals Inc. Closes Non-Brokered Equity Financing
Published on 12/19/2025 at 18:30, 2 days 15 hours ago

Eagle Plains Shareholders Approve all Matters at Annual General Meeting
Published on 12/19/2025 at 14:40, 2 days 19 hours ago

Northern Superior Announces Closing of the Arrangement

View all ACCESSWIRE

EQS Group

Published on 12/22/2025 at 09:30, 35 minutes ago

Huawei's MoM-based Multi-Agent Collaboration System Empowers Core Networks' Transitioning to L4 High Stability
Published on 12/22/2025 at 09:22, 43 minutes ago

Heirs Energies Agrees $750m Afreximbank Financing to Drive Long-Term Growth
Published on 12/22/2025 at 09:19, 46 minutes ago

INDUS acquires media technology specialist
Published on 12/22/2025 at 09:00, 1 hour 4 minutes ago

Original-Research: Cantourage Group SE (von NuWays AG): BUY
Published on 12/22/2025 at 09:00, 1 hour 5 minutes ago

Removal- Paragon Mortgages (No.28) PLC

Les Echos

Published on 12/22/2025 at 09:18, 47 minutes ago

GUILLEMOT CORPORATION: Information regarding the total number of voting rights and shares 11/12/2025
Published on 12/19/2025 at 08:30, 3 days 1 hour ago

Share capital decrease by way of treasury shares cancellation
Published on 12/19/2025 at 07:00, 3 days 3 hours ago

EURAZEO ANNOUNCES A SUCCESSFUL TRANSACTION ACCELERATING ITS ASSET ROTATION
Published on 12/18/2025 at 18:30, 3 days 15 hours ago

Schneider Electric completes transaction to acquire remaining 35% stake in existing Indian JV
Published on 12/18/2025 at 17:45, 3 days 16 hours ago

Cie du Bois Sauvage : Cancellation of own shares

View all LES ECHOS COMFI WIRE